Orexo AB (ORX.ST)
* Says effective July 1st Zubsolv is only preferred buprenorphine/naloxone product within largest fee for service (ffs) medicaid program in U.S., state of Maryland
* signs license agreement with Mundipharma, which obtains ex-us global rights to Zubsolv
* says AstraZeneca acquires all rights to Orexo's OX-CLI project
Earnings vs. Estimates
Analyst Research Reports
Orexo AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
Provider : Thomson Reuters StreetEvents
Provider : GlobalData
Provider : Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.